Overview

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Status:
Withdrawn

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the preliminary efficacy for each combination regimen.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

NKGen Biotech, Inc.
NKMax America, Inc.

Treatments:

Cetuximab
Trastuzumab